Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said it has entered into a research collaboration agreement with PharmaTher Holdings Ltd to evaluate the delivery of 3,4-Methylenedioxymethamphetamine (MDMA) using PharmaTher’s novel microneedle patch (MN-Patch) delivery technology.
PharmaTher completed a non-clinical research study evaluating the delivery of its patch for which results are due early in the second quarter of the year. The results will be used to support a potential human clinical study, the company said.
Based on the results, Revive and PharmaTher will finalize a product and clinical development plan to initiate regulatory discussions for future clinical studies in various indications where MDMA may have promise, including depression, anxiety, abuse disorders and post-traumatic stress disorders, it added.
READ: Revive Therapeutics submits updated briefing package to FDA for Covid treatment
"We are excited about the potential of the MDMA microneedle patch, which will complement our psilocybin programs for mental health and abuse disorders. We look forward to advancing the MDMA patch program that could fill the gaps that we believe could offer an advantage to oral MDMA treatments,” Michael Frank, Revive CEO, said in a statement.
In addition to developing bucillamine for infectious diseases and rare disorders, Revive is building a specialty psychedelics program, which includes psilocybin and MDMA to treat mental health and abuse disorders.
PharmaTher is a specialty pharmaceutical company focused on developing and commercializing KETARX (racemic ketamine) for mental health, neurological and pain disorders.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the US Food and Drug Administration (FDA).
Contact the author at jon.hopkins@proactiveinvestors.com